ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0238

Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0578

Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0474

Real-World Experience of Janus Kinase Inhibitors; Retention and Factors Associated with Discontinuation

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0429

Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0369

Real-World Persistence of Janus Kinase Inhibitors in Biologic-Experienced Patients with Rheumatoid Arthritis

(0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0201

Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals

(0199–0209) Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0572

Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0400

Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0084

Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts

(0067–0097) Rheumatoid Arthritis – Etiology and Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0587

Regulatory Role of IL17 F in the Pannus Formation of Psoriatic Arthritis: A Comparative Study with IL-17A

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0762

Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers

(0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0666

Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023

(0641–0670) Systemic Lupus Erythematosus – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0056

Repository Corticotropin Injection Reduces Inflammation and Bone Turnover Markers in the Murine CIA Model

(0049–0066) Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0465

Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0667

Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN

(0641–0670) Systemic Lupus Erythematosus – Treatment Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].